The former CEO of Opexa made trips to Germany and Australia making connections for futures sites. With Irun R. Cohen on the scientific advisory board, I assume Sheba in Israel would be a future site.
I would not look for any foreign sites until Tovaxin gets FDA approval. The main reason is money. The last finance round was done to have the money to run the current trial.
Opexa already has a vaccine for rheumatoid arthritis using the same principle as Tovaxin, but the most they might do with it will be a small phase I/II trial in Houston. They are also working on an adult stem cell to replace islet cells in type one diabetes.
Best regards, Tim
In 2001, my family helped fund the startup of Opexa. My father served on the Board of Directors of PharmaFrontiers, now Opexa Therapeutics, until the company completed a successful 23-million dollar financing round.